CTSO - シトソ―ベンツ （Cytosorbents Corporation） シトソ―ベンツCTSOのチャート
CTSOの企業情報
| symbol | CTSO |
|---|---|
| 会社名 | Cytosorbents Corp （シトソ―ベンツ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product CytoSorb which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. In addition CytoSorb is used in other inflammatory conditions such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. シトソ―ベンツは、免疫療法に特化した米国の医療会社。多臓器不全を治療するために炎症を調節する血液浄化技術プラットフォ―ムを使用して免疫療法を行う。欧州連合で、体外サイトカインフィルタ｢CytoSorb｣デバイスを販売する｡また血液浄化システム｢HomoDefend｣と血液から有毒な薬を取り除く｢DrugSorb｣を開発する。 CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 110,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. |
| 本社所在地 | 7 Deer Park Drive Suite K Monmouth Junction NJ 08852 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37347 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 84人 |
| url | www.cytosorbents.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ctso |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.01103 |
| 終値（lastsale） | 11.61 |
| 時価総額（marketcap） | 365244133.23 |
| 時価総額 | 時価総額（百万ドル） 360.83980 |
| 売上高 | 売上高（百万ドル） 19.15110 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 345.45086 |
| 当期純利益 | 当期純利益（百万ドル） -14.00454 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytosorbents Corp revenues increased 60% to $10.7M. Net loss increased from $3.3M to $8.8M. Revenues reflect CytoSorb sales increase of 71% to $9.6M Other sales increase from $14K to $88K. Higher net loss reflects General and administrative -other increase of 49% to $7.8M (expense) Stock-based Compensation in SGA increase from $876K to $2.5M (expense). |
CTSOのテクニカル分析
CTSOのニュース
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q3 2021 Results - Earnings Call Transcript 2021/11/07 04:57:44 Seeking Alpha
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results 2021/11/04 20:15:00 PR Newswire
MONMOUTH JUNCTION, N.J., Nov. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports full
Blood Purification Equipment Market Report, Size 2021: Global Trends, Top Players Updates, Future Plans, Industry Impact and Forecast till 2027 | Cytosorbents Corporation, Baxter International, ExThera Medical Corporation, Aethlon Medical, Fresenius SE & 2021/10/19 09:09:22 OpenPR
A comprehensive overview of the Blood Purification Equipment market is recently added by UnivDatos Market Insights to its humongous database. The Blood Purification Equipment report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints,
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs 2021/10/08 11:31:17 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug collaboration with Nuemora) Angion Biomedica Corp. (NASDAQ: ANGN ) Applied DNA Sciences, Inc. (NASDAQ: APDN ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Avenue Therapeutics, Inc.
Massive Growth in Disposable Hemoperfusion Market Set to Witness Huge Growth by 2027 | Biosun Pharmed, Jafron Biomedical, CytoSorbents Corporation 2021/09/15 09:36:12 OpenPR
Hemoperfusion may be a treatment technique during which large volumes of the patients blood are passed over an adsorbent substance so as to get rid of toxic substances from the blood. Adsorption may be a process during which molecules or
CytoSorbents Reports Second Quarter 2021 Financial and Operational Results 2021/08/03 20:15:00 PR Newswire
MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, reports financial and
CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery 2021/07/06 08:12:00 Benzinga
CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference 2021/05/27 00:00:00 BioSpace
CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company''s progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021.
CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit 2021/05/19 11:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., May 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the